What Sinocelltech does

Sinocelltech (北京神州细胞生物技术集团股份公司; Shanghai STAR Market ticker 688520) is a Beijing-based, publicly-traded Chinese biopharmaceutical company founded in 2002 by Dr. Xie Liangzhi (an internationally renowned biologics R&D and industrialization expert) that develops, manufactures, and commercializes biological drugs spanning monoclonal antibodies, recombinant proteins, and vaccines. The company has five marketed products in China across four disease areas: oncology (安平希®/SCT400 rituximab biosimilar for non-Hodgkin's lymphoma, 安贝珠®/SCT510 bevacizumab biosimilar for solid tumors, 安佑平®/SCT-I10A anti-PD-1 antibody for head and neck squamous cell carcinoma and hepatocellular carcinoma), autoimmune diseases (安佳润®/SCT630 adalimumab biosimilar for rheumatoid arthritis, psoriasis, ankylosing spondylitis, and Crohn's disease), hemophilia A (安佳因®/SCT800, a third-generation recombinant Factor VIII), and infectious disease prevention (SCTV01C bivalent and SCTV01E-2 quadrivalent COVID-19 vaccines, the latter being the world's first approved broad-spectrum 4-valent vaccine covering XBB variants).

The company's technology foundation rests on proprietary high-efficiency, high-throughput platforms spanning the entire biologics R&D-to-commercialization chain, including recombinant protein expression, monoclonal antibody development, and recombinant protein vaccine engineering with integrated drug substance, finished product, and adjuvant manufacturing. Manufacturing capacity is a stated differentiator, with a recombinant Factor VIII drug substance line designed for up to 10 billion IU annually and commercial-scale vaccine capacity in the hundreds of millions of doses per year. The pipeline includes nine clinical-stage candidates, most notably SCT1000 (world's first 14-valent HPV vaccine in Phase III, targeting cervical cancer prevention coverage up to 96%), SCTV04C for shingles, SCTV02 for RSV, SCT520FF for wet age-related macular degeneration, and bispecific antibodies including SCTB35 (CD20xCD3).

Sinocelltech makes money through direct biopharmaceutical product sales in China via an in-house commercial team built around its first approved product SCT800, complemented by a strategic distribution partnership with 上药科园 (Shang Yao Ke Yuan) for COVID-19 vaccine distribution across 31 provinces and 2,000+ district/county CDC vaccination points with a 500-person supply chain team. End customers are Chinese patients reached through hospital pharmacy and CDC channels across four therapeutic segments; the company has no identified enterprise customer concentration. Recent reimbursement milestones include SCT400 entering the National Medical Insurance Catalog in December 2023 and SCT-I10A in December 2025. The company went public on the Shanghai STAR Market in June 2020 and reported approximately 650 million yuan in revenue for Q1–Q3 2022.

Name

Sinocelltech

Legal name

北京神州细胞生物技术集团股份公司

Website

https://sinocelltech.com

Company type

Public

Founded year

2002

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Sinocelltech (SSE: 688520) is a Beijing-based Chinese biopharmaceutical company developing and commercializing monoclonal antibodies, recombinant proteins, and vaccines, with five marketed products in oncology, autoimmune disease, hemophilia A, and infectious disease prevention across China.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industry

Travel & Tropical Disease Vaccines (HLAIAEAE)

Keywords

• Biopharmaceutical products
• Monoclonal antibodies
• Recombinant proteins
• Therapeutic vaccines
• Biosimilar drugs

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. Biopharmaceutical Product Sales: Sinocelltech generates revenue through the sale of approved biopharmaceutical products, including 安佳因 (SCT800, approved July 2021 for hemophilia A), 安平希 (SCT400, approved August 2022 for non-Hodgkin's lymphoma), 安贝珠 (SCT510, approved June 2023 for solid tumors), 安佳润 (SCT630, adalimumab biosimilar approved June 2023 for autoimmune diseases), and 安佑平 (SCT-I10A, approved February 2025 for head and neck squamous cell carcinoma and hepatocellular carcinoma).
2. Vaccine Product Sales: Revenue from COVID-19 vaccines (SCTV01C and SCTV01E-2) distributed via partnership with 上药科园 across China, including emergency use authorization for SCTV01E-2 granted in December 2023.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Sinocelltech is a Chinese biopharmaceutical company that develops, manufactures, and commercializes innovative biologics including monoclonal antibodies, recombinant proteins, and vaccines. Its marketed and pipeline products address oncology, autoimmune and inflammatory diseases, hemophilia A, age-related macular degeneration, and infectious diseases including COVID-19, HPV, RSV, and shingles.

Product overview

Sinocelltech is a biopharmaceutical company founded in 2002 and listed on the STAR Market (stock code: 688520) that develops, manufactures, and commercializes biological drugs including monoclonal antibodies, recombinant proteins, and vaccines. The company has 5 marketed products in China: 安佳因® (SCT800) for hemophilia A, 安平希® (SCT400) and 安贝珠® (SCT510) for oncology, 安佳润® (SCT630) for autoimmune diseases, and 安佑平® (SCT-I10A) for cancer immunotherapy. Additionally, the company has a COVID-19 vaccine portfolio including 安诺能®4 (quadrivalent) and 安诺能®2 (bivalent) recombinant protein vaccines. The pipeline includes 9 clinical-stage products spanning vaccines (14-valent HPV, shingles, RSV), bispecific antibodies for cancer, and monoclonal antibodies for autoimmune diseases and ophthalmology. The company operates technology platforms for recombinant protein, monoclonal antibody, and vaccine development with integrated manufacturing capabilities.

Differentiator

Problem solved

Functional benefit

Brands

• 安佳因® (SCT800): 重组人凝血因子VIII - Recombinant human coagulation factor VIII for hemophilia A treatment
• 安平希® (SCT400)
• 安贝珠® (SCT510)
• 安佑平® (SCT-I10A)
• 安佳润® (SCT630)
• 安诺能®2 (SCTV01C)
• 安诺能®4 (SCTV01E-2)
• SCT1000

Products and services

• SCT800 (Anjia Yin, 安佳因)

Quantifiable outcome

• 14-valent HPV vaccine (SCT1000) expected to raise cervical cancer prevention protection rate to 96%
• +3 more outcomes

Named customers2 records

Segments5 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• 上药科园 (Shang Yao Ke Yuan)coreChannel Partner/ Reseller/ Distributor · 14 February 2023Sinocelltech entered a strategic partnership with 上药科园 (Shang Yao Ke Yuan) for distribution of its COVID-19 vaccines (Anneng series) across China. 上药科园 has a wide vaccine distribution network covering 31 provinces, municipalities, and autonomous regions, with over 2000 district/county CDC vaccination points and a 500-person vaccine team providing full supply chain services from bidding and market access to terminal coverage.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Innovent Biologics: Chinese biotech developing and commercializing monoclonal antibodies including a leading PD-1 (tyvyt/sintilimab). Directly comparable to Sinocelltech as a domestic Chinese innovator with commercial mAb franchises in oncology and a pipeline of biosimilars and novel biologics.
• Shanghai Junshi Biosciences: Chinese PD-1 pioneer (toripalimab/拓益) with a broader pipeline of mAbs and innovative biologics across oncology and autoimmune. Comparable to Sinocelltech on the PD-1 mAb head-to-head and as a fellow Chinese-listed STAR/HK biotech with similar target indications.
• BeiGene: Global Chinese-founded oncology biotech commercializing tislelizumab (百泽安, PD-1) and Brukinsa. Comparable on monoclonal antibody oncology development, China-US dual listing profile, and breadth of clinical pipeline overlapping with Sinocelltech's oncology focus.
• Shanghai Henlius Biotech: Chinese biosimilar specialist (rituximab, trastuzumab, bevacizumab, adalimumab) with global commercialization. Closely comparable to Sinocelltech's rituximab (SCT400), bevacizumab (SCT510) and adalimumab (SCT630) biosimilar franchise, and a fellow STAR/HK-listed Chinese biotech.
• Akeso Inc: Chinese biotech developing bispecific antibodies and mAbs in oncology and autoimmune. Comparable to Sinocelltech on the CD20xCD3 bispecific (SCTB35), anti-IL-17 (SCT650C) and PD-1 programs, and as a fellow innovation-focused Chinese mAb company.
• Cansino Biologics: Chinese vaccine developer (Convidecia COVID-19 vaccine, MCV2/MCV4 meningococcal, inhaled TB). Comparable to Sinocelltech's vaccine business — particularly the recombinant protein COVID-19 and broader recombinant vaccine pipeline (HPV, RSV, shingles).
• Walvax Biotechnology: Chinese vaccine manufacturer with a broad portfolio including COVID-19, HPV and pneumococcal vaccines. Comparable to Sinocelltech on the HPV and COVID-19 vaccine franchises, and as a domestic Chinese vaccine company with scaling manufacturing capacity.

Broad incumbents

• WuXi Biologics: Largest Chinese biologics CDMO. Comparable to Sinocelltech on biologics manufacturing technology and scale, though WuXi operates as a contract services platform rather than a product company. Often considered a benchmark for biologics production capabilities in China.
• China Biologic Products Holdings: Chinese plasma-derived and recombinant blood-product manufacturer including factor VIII. Highly comparable to Sinocelltech's SCT800 recombinant factor VIII product and the hemophilia A commercial franchise.

Others

• Shanghai Pharmaceuticals Holding: Largest Chinese pharmaceutical distributor and manufacturer. Comparable as the parent of Sinocelltech's distribution partner 上药科园, and as a broader reference for the China biopharma distribution and reimbursement environment in which Sinocelltech operates.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sinocelltech